TLC 388: Clinical Trials

3 trials of TLC 388, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 terminated, 1 completed. 3 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 13Terminated 2, Completed 1
Phase 22Terminated 2

Follow TLC 388: new trials by email Literature Review of TLC 388 trials Research Report on TLC 388

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Lipotecan Based Concurrent Chemoradiotherapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis
Lipotecan - HepatoCellular Carcinoma, Portal Vein Tumor Thrombosis
Phase 1 / Phase 2TerminatedTaiwan Liposome Company12017-04-142018-11-06
A Dose-escalation Study of Lipotecan® Plus Radiotherapy in Locally Advanced Hepatocellular Carcinoma
Lipotecan® (TLC388) - Carcinoma, Hepatocellular
Phase 1 / Phase 2TerminatedTaiwan Liposome Company32011-10-272018-08-21
Phase I Study of Intravenous Lipotecan® (TLC388 HCl for Injection) in Patients With Advanced Solid Tumors
Lipotecan - Advanced Solid Tumors
Phase 1CompletedTaiwan Liposome Company542008-09-012019-11-18

Conditions studied

Carcinoma, Hepatocellular (2)

Sponsors

Taiwan Liposome Company (3)

Countries

Taiwan (3)  ·  United States (1)

Top investigators

Carl Brown, PhD (1)  ·  Chen-Hsi Hsieh, MD (1)  ·  Jacqueline Whang-Peng, MD (1)  ·  Min-Hsiung Kao (1)  ·  Tsang-En Wa, MD (1)  ·  Yee Chao, MD (1)